The problem:
The NHS spent £8.3 billion on wound care between 2017 and 2018, with £5.6 billion on chronic and complex wounds. Despite this investment, 51% of complex wounds failed to close after 12 months of treatment. This problem is growing, with associated markets demonstrating a 5.5% compound annual growth rate, a problem that is reflected worldwide and linked with rising incidences of diabetes, obesity and aging populations. There’s a clear market need for a technology that aims to address problems in the care of chronic and complex wounds, rates of infection and time to wound closure.
The solution:
Corryn Biotechnologies’ novel technology allows the production and application of advanced micro and nanofibrous materials directly onto wounds at the point of care, without the need for any technical expertise. This will allow a new generation of materials, which have proven beneficial in academic literature, to be applied to wounds directly.
Over the next 18 months, the company will initiate and complete clinical trials to demonstrate the safety and usability of the technology, as well as beginning to quantify the benefit of this approach and materials over existing technologies.
Traction:
- EPSRC’s Redistributed Manufacturing in Healthcare Network provided funding for first prototypes.
- The Welsh Government funded AgorIP has provided funds and other resources for IP development and protection.
